We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Oncimmune Holdings plc (ONC) Ordinary 1p

Sell:14.60p Buy:15.20p 0 Change: 0.1p (0.68%)
Market closed |  Prices as at close on 20 December 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:14.60p
Buy:15.20p
Change: 0.1p (0.68%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 20 December 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:14.60p
Buy:15.20p
Change: 0.1p (0.68%)
Market closed |  Prices as at close on 20 December 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Oncimmune Holdings plc is a United Kingdom-based company, which is engaged in the autoantibody profiling to the pharmaceutical and biotechnology industry. The Company primarily focused on the growing fields of immuno-oncology, autoimmune disease, and infectious diseases. The Company's principal activity is the development and commercialization of technologies that enable cancer diagnosis. Its service offerings include ImmunoINSIGHTS. The ImmunoINSIGHTS service business leverages its technology platform and methodologies across multiple diseases, to offer life-science organizations actionable insights for therapies across the development and product lifecycle. Its immune-profiling technology helps the Company in identifying trial participants and patients into clinically relevant subgroups, which enables the development of targeted treatments. The Company's subsidiary is Oncimmune Germany GmbH.

Contact details

Address:
1 Park Row
LEEDS
LS1 5AB
United Kingdom
Telephone:
+44 (0115) 8231869
Website:
https://www.oncimmune.com/

Important dates

Future events
There are no future events available.
Past events
General meeting 08 November 2024 08/11/24
Trading Announcement 31 October 2024 31/10/24
Trading Announcement 09 September 2024 09/09/24
Interim results 21 May 2024 21/05/24
General meeting 02 April 2024 02/04/24
Final results 29 February 2024 29/02/24
AGM 26 February 2024 26/02/24

General stock information

EPIC:
ONC
ISIN:
GB00BYQ94H38
Market cap:
£16.54 million
Shares in issue:
111.77 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Martin Gouldstone
    Chief Executive Officer, Director
  • Martin Hudson
    Finance Director
  • Ron Kirschner
    Chief Operating Officer, Company Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.